Medtronic plc

Medtronic plc filed its annual report on Form 10-K, detailing its business operations across its Cardiovascular, Neuroscience, and Medical Surgical portfolios. A significant event noted is the separation of its Diabetes Business, which was completed through an IPO of MiniMed Group, Inc. in March 2026. The report emphasizes Medtronic's mission and strategic focus on innovation, patient outcomes, and leveraging technology like AI and data analytics. It provides an overview of the company's diverse product lines and its commitment to human capital management and research and development.

Medtronic plc reported strong financial results for its fourth quarter and full fiscal year 2026, marking the highest annual revenue growth in 10 years. The company announced Q4 revenue of $9.8 billion, up 9.9% as reported and 6.6% organically, with full-year revenue at $36.4 billion, up 8.4% as reported and 5.8% organically. Key growth drivers included the Cardiovascular and Medical Surgical portfolios, with notable strength in Cardiac Ablation Solutions. Medtronic also declared its 49th consecutive annual dividend increase. The company provided guidance for FY27, expecting organic revenue growth of 6.75% to 7.25% and non-GAAP diluted EPS between $5.90 and $6.00.

Medtronic plc announced that Brett Wall will depart from his role as Executive Vice President and President, Neuroscience Portfolio. Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will succeed him, effective June 1, 2026. Mr. Wall will remain with the company until September 1, 2026, to facilitate a smooth transition and will receive severance benefits consistent with Medtronic's executive severance practices.

Medtronic plc announced that an unauthorized third party accessed data in some of its information technology systems. The company promptly contained the incident, activated its response protocols, and engaged leading external cybersecurity experts. Based on its investigation to date, Medtronic has not identified any impact to its products, patient safety, connections to customers, manufacturing and distribution operations, or financial reporting systems. The company does not currently expect the incident to have a material impact on its business or financial results.